Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib and VS-4718, and dual PI3K/mTOR inhibitor VS-5584. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.01 (0.83%)
Data as of 01/13/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
12/05/16Verastem Presents Phase 2 DYNAMO® Clinical Data at ASH 2016 Annual Meeting
Duvelisib Treatment Results in a 46% ORR in Patients with Double Refractory Indolent Non-Hodgkin Lymphoma BOSTON--(BUSINESS WIRE)--Dec. 5, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy of duvelisib in patients with indolent non-Hodgkin lymphoma (iNHL) that is double ... 
Printer Friendly Version
11/07/16Verastem Reports Third Quarter 2016 Financial Results
Company Adds Late-Stage, Complementary Oncology Product Candidate Duvelisib to Pipeline BOSTON--(BUSINESS WIRE)--Nov. 7, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate developments. “Last week, we announced the inlicensing of the late-stage oncology ... 
Printer Friendly Version
11/03/16Verastem Announces Presentations at ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--Nov. 3, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society of Hematology (ASH) 2016 Annual Meeting, being held December 3-6, 2016 in San Diego. Data from DYNAMO®, a Phase 2 monotherapy ... 
Printer Friendly Version
11/02/16Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem’s Pipeline Duvelisib Has Demonstrated Clinical Activity in Lymphoid Malignancies License of Duvelisib Aligns with Verastem’s Focus on Targeting the Tumor Microenvironment Verastem Management to Host Conference Call and Webcast at 8:30 a.m. ET Today BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2016-- ... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.